Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• A diagnosis of colorectal cancer (specifically adenocarcinoma) confirmed by tissue testing
• Liver metastases (cancer spread to the liver) confirmed by imaging or tissue testing
• Liver metastases that a specialist team has determined cannot be surgically removed, based on specific medical criteria such as the number of tumours, their location, or the amount of healthy liver tissue that would remain after surgery
• Cancer that has a specific genetic mutation known as mutated RAS and BrafV600E
• No previous treatment for the liver metastases, including chemotherapy, surgery, radiation, a procedure called TACE, or targeted therapy
• No confirmed cancer spread outside the liver, as shown by scans (small lung or lymph node spots under 10mm that are hard to identify may still be considered — confirm with trial site)
• Blood cell counts within acceptable ranges: platelets, white blood cells, and neutrophils all above specified levels
• Liver-related blood test results within acceptable ranges (bilirubin and liver enzyme levels)
• No fluid build-up in the abdomen, normal blood clotting, and protein (albumin) levels at or above a certain threshold
• Liver function rated as Child-Pugh grade A (a measure of how well the liver is working)
• Kidney function within an acceptable range, based on blood tests or a calculated measure
• A physical performance score of 0 or 1 on the ECOG scale, meaning the person is fully active or has only minor limitations in daily activity
• Life expectancy greater than 3 months
• Willing and able to provide written informed consent

Who may not be able to join:

• Cancer that has spread outside the liver, or a primary tumour that cannot be completely removed with surgery
• Liver metastases that developed within 1 year of finishing a specific type of chemotherapy (FOLFOX or XELOX) given after earlier cancer surgery
• Severe arterial blockages or fluid build-up in the abdomen
• A tendency to bleed or a blood clotting disorder
• Severely uncontrolled high blood pressure or high blood pressure affecting the brain
• Serious uncontrolled conditions such as infection or diabetes
• Significant heart or blood vessel disease, including stroke or heart attack within the past 6 months, uncontrolled high blood pressure, unstable chest pain, heart failure, or certain heart rhythm problems requiring medication
• A history or current presence of nervous system conditions such as a brain tumour, epilepsy not controlled by standard treatment, cancer spread to the brain, or a history of stroke
• A diagnosis of another cancer within the past 5 years (with exceptions for certain types of skin cancer or cervical changes treated with surgery)
• Participation in another clinical trial using an experimental drug within the past 28 days
• Ongoing side effects from previous chemotherapy that have not resolved, such as nerve damage of a certain severity — this may affect eligibility for treatments containing oxaliplatin (confirm with trial site)
• A known allergy to any of the medications used in this trial
• Women who could become pregnant (within 2 years of last menstrual period) or men who could father a child, if they are not using or have declined to use an approved non-hormonal contraceptive method; also excludes those who are pregnant or breastfeeding
• Unwillingness or inability to follow the trial's requirements
• Any other medical condition, complication, or finding that the trial team considers a reason to avoid the study treatment or that could put the person at risk of serious treatment-related harm

Important: Always verify eligibility with the trial site directly before applying.